Want to see KR:002210 full AI Analyst Report?
Dongsung Pharmaceutical Co., Ltd. (002210) AI Stock Analysis
Dongsung Pharmaceutical Co., Ltd.
(Korea Exchange:002210)
The score is primarily held back by weak financial performance driven by ongoing operating losses and persistent negative operating/free cash flow, despite improved leverage and modest revenue growth. Technical indicators add a slightly negative tilt with bearish MACD and below-neutral RSI. Valuation is not supportive given the negative P/E (loss-making) and no dividend yield data.
Dongsung Pharmaceutical Co., Ltd. (002210) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 29.19B
- Dividend Yield
- ―
- Average Volume (3M)
- 151.51K
- Price to Earnings (P/E)
- -4.1
- Beta (1Y)
- -0.02
- Revenue Growth
- -9.11%
- EPS Growth
- 79.32%
- Country
- KR
- Employees
- 307
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Dongsung Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Dong Sung Bio Pharm.Co.,Ltd. is a South Korean company with diverse operations spanning pharmaceuticals, cosmetics, hair dye manufacturing, and photodynamic therapy. Its extensive product range includes a broad selection of over-the-counter (OTC) med...
Dongsung Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Despite modest TTM revenue growth (+2.7%) and decent gross margin (~41–44%), profitability remains meaningfully negative (about -10% operating margin and -14% net margin). The balance sheet has improved with sharply lower leverage (debt-to-equity ~0.44 TTM vs ~2.74 in 2025), but negative returns and persistent losses limit the score.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
12Very Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 82.07B | 87.17B | 88.45B | 88.59B | 93.33B | 84.41B |
| Gross Profit | 33.85B | 36.36B | 38.88B | 41.37B | 42.06B | 33.54B |
| EBITDA | -6.47B | -20.73B | -1.88B | 3.42B | 1.58B | -1.44B |
| Net Income | -11.52B | -25.74B | -7.25B | -2.07B | -2.12B | -4.31B |
Balance Sheet | ||||||
| Total Assets | 159.77B | 168.44B | 151.91B | 114.97B | 107.70B | 104.58B |
| Cash, Cash Equivalents and Short-Term Investments | 37.47B | 3.86B | 3.15B | 6.44B | 4.09B | 5.14B |
| Total Debt | 38.61B | 64.13B | 52.09B | 43.27B | 37.04B | 29.31B |
| Total Liabilities | 72.28B | 145.07B | 96.73B | 75.17B | 64.89B | 58.14B |
| Stockholders Equity | 87.49B | 23.37B | 55.18B | 39.80B | 42.81B | 46.44B |
Cash Flow | ||||||
| Free Cash Flow | -26.16B | -14.16B | -12.41B | -5.22B | -4.53B | -5.08B |
| Operating Cash Flow | -25.26B | -12.86B | -9.94B | -4.29B | -3.88B | -2.75B |
| Investing Cash Flow | 1.64B | 3.14B | -6.86B | -927.71M | 638.29M | -9.70B |
| Financing Cash Flow | 55.45B | 10.46B | 13.51B | 7.57B | 4.24B | 1.23B |
Dongsung Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:002210, the sentiment is Negative. The current price of 1196.00 is below the 20-day moving average (MA) of 1261.55, below the 50-day MA of 1359.24, and above the 200-day MA of 1111.09, indicating a neutral trend. The MACD of -31.20 indicates Positive momentum. The RSI at 37.69 is Neutral, neither overbought nor oversold. The STOCH value of 17.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:002210.
Dongsung Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
- KR:00221045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:002210 | 45Neutral | KRW 112.91B | -4.08 | ― | ― | -9.11% | 79.32% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:002210 | Dongsung Pharmaceutical Co., Ltd. | 1196.00 | 223.00 | 22.92% | |
| KR:034940 | ChoA Pharmaceutical Co., Ltd. | 1704.00 | -3551.00 | -67.57% | |
| KR:036480 | Daesung Microbiological Laboratories Co., Ltd. | 5490.00 | -1607.91 | -22.65% | |
| KR:053950 | Kyungnam Pharm Co., Ltd. | 1675.00 | -1925.00 | -53.47% | |
| KR:298060 | POONGJEON PHARMACY CO., LTD. | 2350.00 | -3340.00 | -58.70% | |
| KR:398120 | SG Healthcare Co., Ltd. | 2040.00 | -845.00 | -29.29% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026